Nutrition and the transplant candidate

Vera C. Mazurak, Puneeta Tandon, Aldo J. Montano‐Loza – 26 October 2017 – Cirrhosis is the most common indication for liver transplantation (LT) worldwide. Malnutrition is present in at least two‐thirds of patients with cirrhosis awaiting LT. It negatively impacts survival, quality of life, and the ability to respond to stressors, such as infection and surgery. Muscle wasting or sarcopenia is the most objective feature of chronic protein malnutrition in cirrhosis, and this condition is associated with increased morbidity and mortality before and after LT.

Periostin promotes malignant potential by induction of epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma

Masaaki Mino, Keishi Kanno, Kousuke Okimoto, Akiko Sugiyama, Nobusuke Kishikawa, Tomoki Kobayashi, Junya Ono, Kenji Izuhara, Tsuyoshi Kobayashi, Toshikazu Ohigashi, Hideki Ohdan, Susumu Tazuma – 25 October 2017 – Periostin, a secreted matricellular protein, has been reported to induce epithelial‐mesenchymal transition (EMT), which increases motility and invasiveness in various epithelial cancer cells.

LiverLearning®: 2017 Hepatitis Debrief

This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.Michael W. Fried Insook Kim Insook Kim, PhD is a clinical pharmacology team leader for gastroenterology and hepatology products in the Office of Clinical Pharmacology at FDA. Since she joined FDA as a clinical pharmacology reviewer in 2007, she has been involved in numerous IND and NDA review and has provided regulatory and scientific guidance for product development in the areas of gastroenterology, hepatology, and inborn errors of metabolism.

Subscribe to